|
|||||
|
Quinine should no longer be the drug of choice for treating severe malaria, according to an updated systematic review by Cochrane researchers. It is now evident that the antimalarial drug artesunate, which is derived from herbs used in Chinese medicine, is more effective at preventing death in patients with severe malaria. Severe malaria . . . → Read More: Artesunate more effective against severe malaria A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer. “Thanks to advances in LED technology, which mean that controlled doses of light can be effectively delivered at specific wavelengths, we were able to develop a viable alternative.” Cevira® is a drug-device . . . → Read More: First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix In the years since the AIDS epidemic began, it has become clear that there is substantial variation in the way that individuals respond to HIV infection. Although most progress quickly from initial infection to immunodeficiency, a small subset survive for long periods without developing symptoms. These patients, dubbed elite controllers, display undetectable levels of . . . → Read More: Elite controllers’ T cells resist HIV-1 infection by selective upregulation of protein p21 The incidence and mortality associated with hepatocellular carcinoma (HCC) have been increasing worldwide, and hepatitis C virus (HCV) infection plays an important role in the pathogenesis of HCC. Previous studies have suggested that host factors, such as sex, alcohol consumption, smoking, diabetes mellitus, and obesity, are important risk factors for HCC. Meanwhile, it has . . . → Read More: Research: Underweight HCV-infected patients tend to be older at HCC onset Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response. The bacterium secretes a protein called NleH1 that directs the host immune enzyme IKK-beta to alter specific . . . → Read More: Study Helps Explain How Pathogenic E. coli Bacterium Causes Illness Oral vaccines could prevent up to 60 percent of cholera cases in the first two years after vaccination, according to a new review of vaccine studies. The vaccines have been shown to provide protection within one month of vaccination, but data from studies of older versions of the vaccines suggest that protection is . . . → Read More: New review: Oral vaccines can prevent up to 60% of cholera cases in first two years Those working for healthier humans around the globe are making headway in fighting communicable diseases such as AIDS, malaria and diarrheal illness, according to research from the Frederick S. Pardee Center for International Futures in the University of Denver’s (DU) Josef Korbel School of International Studies. The center recently released the third in . . . → Read More: Global chronic disease burdens are increasing rapidly: Research Research has shown that playing a musical instrument can help nourish, cultivate, and increase intelligence in children, but playing a used instrument also can pose a potentially dangerous health risk. Used woodwind and brass instruments were found to be heavily contaminated with a variety of bacteria and fungi, many of which are associated . . . → Read More: Research: Used instrument can pose dangerous health risk in children Can probiotics prevent pneumonia in patients breathing with the help of ventilators? That’s just one question researchers at Washington University School of Medicine in St. Louis hope to answer as part of innovative new studies to reduce infections in health-care settings. Their research is funded by a grant from the U.S. Centers for Disease . . . → Read More: Novel Strategies Target Health-Care-Associated Infections Providing clues into why the severity of a common parasitic infection can vary greatly from person to person, a new Johns Hopkins study shows that each one of three strains of the cat-borne parasite Toxoplasma gondii sets off a unique reaction in the nerve cells it invades. Past research suggests that the parasite, estimated . . . → Read More: Toxoplasmosis; The Strain Explains Severity Of Infection A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections. The study has been published online in advance of print. Compared with younger adults, the elderly are at higher risk of becoming seriously ill or . . . → Read More: Study provides insight into aging immune system A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections. The study has been published online in advance of print. Compared with younger adults, the elderly are at higher risk of becoming seriously ill or . . . → Read More: Study provides insight into why older adults are so vulnerable to pneumonia Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response. The bacterium secretes a protein called NleH1 that directs the host immune enzyme IKK-beta to alter specific . . . → Read More: Scientists show how E. coli strain causes infection in individuals Alum is an adjuvant (immune booster) used in many common vaccines, and Canadian researchers have now discovered how it works. The research by scientists from the University of Calgary’s Faculty of Medicine is published in the March 13 online edition of Nature Medicine. The new findings will help the medical community produce more effective . . . → Read More: New findings may open doors for vaccine development against HIV, tuberculosis Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB (formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C® DNA vaccine for hepatitis C virus (HCV), delivered by Inovio’s proprietary electroporation . . . → Read More: ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV |
|||||
|
Copyright © 2012 Biomed Middle East - All Rights Reserved |
|||||
